Latest news

• Gilead’s Trodelvy granted FDA priority review for metastatic breast cancer

  overall survival in patients who had received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

• Gilead Sciences announce positive results for Trodelvy in breast cancer patients

  prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.

• NICE approval for Lilly's Verzenios is “fantastic news for thousands of women”

  The committee heard that CDK4/6 inhibitors like abemaciclib were welcomed by patients because they can delay the time before their cancer gets worse and so delay or avoid the need ... CDK4/6 inhibitors like Verzenios block proteins in cancer cells,

• Novartis' Kisqali shows long-term improvements in breast cancer patients

  Both drugs are CDK4/6 inhibitors and are indicated in the post-menopausal, metastatic setting.

• Kisqali combination follows Verzenio onto Cancer Drugs Fund

  The ruling is good news for the company, which is vying with two other treatments in the same CDK4/6 inhibitors class, Eli Lilly’s Verzenio and market leader, Pfizer’s